{
    "success": true,
    "data": {
        "type": "ETF",
        "ucits": true,
        "replication_method": "physical",
        "derivatives": true,
        "swaps": true,
        "inverse": false,
        "leverage": false,
        "complex_factors": [
            "Derivatives for investment purposes",
            "Counterparty risk",
            "Collateral risk",
            "Concentration Risk",
            "High Risk Category"
        ],
        "classification": "complex",
        "supporting_data": "The Fund aims to replicate the Solactive Genomics v2 Index. While the primary investment strategy is to invest in equity securities, the Fund may also invest in financial derivative instruments (FDIs), specifically total return 'unfunded' OTC swaps and exchange-traded equity futures for investment purposes. The KIID explicitly states that 'Derivatives are subject to counterparty risk... and are highly sensitive to underlying price movements... and therefore come with a greater risk.' This direct mention of derivatives used for investment purposes, coupled with the explicit identification of counterparty and collateral risks (implied by the use of OTC swaps), triggers a complex classification according to MiFID II rules. Furthermore, the Fund's high risk category (7 out of 7) due to the volatility of its underlying investments, while not solely determinative, is a contributing factor to its overall risk profile, which, when combined with derivative usage, reinforces the complex classification. The document also mentions the possibility of using FDIs to hedge against negative currency movements, which, although for hedging, still introduces derivative usage."
    }
}